These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 21510823)

  • 21. Gene expression profiles of murine fatty liver induced by the administration of valproic acid.
    Lee MH; Hong I; Kim M; Lee BH; Kim JH; Kang KS; Kim HL; Yoon BI; Chung H; Kong G; Lee MO
    Toxicol Appl Pharmacol; 2007 Apr; 220(1):45-59. PubMed ID: 17292431
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Endoplasmic reticulum stress involved in the course of lipogenesis in fatty acids-induced hepatic steatosis.
    Liu J; Jin X; Yu CH; Chen SH; Li WP; Li YM
    J Gastroenterol Hepatol; 2010 Mar; 25(3):613-8. PubMed ID: 19929925
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gene expression profiles of murine fatty liver induced by the administration of methotrexate.
    Lee MH; Hong I; Kim M; Lee BH; Kim JH; Kang KS; Kim HL; Yoon BI; Chung H; Kong G; Lee MO
    Toxicology; 2008 Jul; 249(1):75-84. PubMed ID: 18502557
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Novel aspects of PPARalpha-mediated regulation of lipid and xenobiotic metabolism revealed through a nutrigenomic study.
    Martin PG; Guillou H; Lasserre F; Déjean S; Lan A; Pascussi JM; Sancristobal M; Legrand P; Besse P; Pineau T
    Hepatology; 2007 Mar; 45(3):767-77. PubMed ID: 17326203
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Strategies for the early detection of drug-induced hepatic steatosis in preclinical drug safety evaluation studies.
    Amacher DE
    Toxicology; 2011 Jan; 279(1-3):10-8. PubMed ID: 20974209
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Basic principles of interpretation of hepatocellular hypertrophy in risk assessment in Japan].
    Yoshida M; Umemura T; Kojima H; Inoue K; Takahashi M; Uramaru N; Kitamura S; Abe K; Tohkin M; Ozawa S; Yoshinari K
    Shokuhin Eiseigaku Zasshi; 2015; 56(2):42-8. PubMed ID: 25925075
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Multi-Parametric Fluorescent Assay for the Screening and Mechanistic Study of Drug-Induced Steatosis in Liver Cells in Culture.
    Tolosa L; Gómez-Lechón MJ; Donato MT
    Curr Protoc Toxicol; 2017 May; 72():14.15.1-14.15.11. PubMed ID: 28463417
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Drug-induced liver steatosis and phospholipidosis: cell-based assays for early screening of drug candidates.
    Donato MT; Gómez-Lechón MJ
    Curr Drug Metab; 2012 Oct; 13(8):1160-73. PubMed ID: 22746303
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Advantageous use of HepaRG cells for the screening and mechanistic study of drug-induced steatosis.
    Tolosa L; Gómez-Lechón MJ; Jiménez N; Hervás D; Jover R; Donato MT
    Toxicol Appl Pharmacol; 2016 Jul; 302():1-9. PubMed ID: 27089845
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Manifestations of chemically induced liver damage.
    Batt AM; Ferrari L
    Clin Chem; 1995 Dec; 41(12 Pt 2):1882-7. PubMed ID: 7497649
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Opinion: understanding 'global' systems biology: metabonomics and the continuum of metabolism.
    Nicholson JK; Wilson ID
    Nat Rev Drug Discov; 2003 Aug; 2(8):668-76. PubMed ID: 12904817
    [No Abstract]   [Full Text] [Related]  

  • 32. Effects of ozone exposure on lipid metabolism in Huh-7 human hepatoma cells.
    Peng J; Wang S; Wang Y; Yu W; Zha Y; Gao S
    Front Public Health; 2023; 11():1222762. PubMed ID: 37521985
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification of the Potential Molecular Mechanisms Linking RUNX1 Activity with Nonalcoholic Fatty Liver Disease, by Means of Systems Biology.
    Bertran L; Eigbefoh-Addeh A; Portillo-Carrasquer M; Barrientos-Riosalido A; Binetti J; Aguilar C; Ugarte Chicote J; Bartra H; Artigas L; Coma M; Richart C; Auguet T
    Biomedicines; 2022 Jun; 10(6):. PubMed ID: 35740337
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Flame Retardants-Mediated Interferon Signaling in the Pathogenesis of Nonalcoholic Fatty Liver Disease.
    Negi CK; Khan S; Dirven H; Bajard L; Bláha L
    Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33924165
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Drug-induced steatohepatitis.
    Dash A; Figler RA; Sanyal AJ; Wamhoff BR
    Expert Opin Drug Metab Toxicol; 2017 Feb; 13(2):193-204. PubMed ID: 27759439
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adverse Outcome Pathways as Tools to Assess Drug-Induced Toxicity.
    Vinken M
    Methods Mol Biol; 2016; 1425():325-37. PubMed ID: 27311472
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mechanistically linked serum miRNAs distinguish between drug induced and fatty liver disease of different grades.
    Liu Z; Wang Y; Borlak J; Tong W
    Sci Rep; 2016 Apr; 6():23709. PubMed ID: 27045805
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adverse Outcome Pathways and Drug-Induced Liver Injury Testing.
    Vinken M
    Chem Res Toxicol; 2015 Jul; 28(7):1391-7. PubMed ID: 26119269
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of novel clinical factors associated with hepatic fat accumulation in extreme obesity.
    Gerhard GS; Benotti P; Wood GC; Chu X; Argyropoulos G; Petrick A; Strodel WE; Gabrielsen JD; Ibele A; Still CD; Kingsley C; DiStefano J
    J Obes; 2014; 2014():368210. PubMed ID: 25610640
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Model steatogenic compounds (amiodarone, valproic acid, and tetracycline) alter lipid metabolism by different mechanisms in mouse liver slices.
    Szalowska E; van der Burg B; Man HY; Hendriksen PJ; Peijnenburg AA
    PLoS One; 2014; 9(1):e86795. PubMed ID: 24489787
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.